177 related articles for article (PubMed ID: 11356159)
1. Resistance to thyroid hormone, and peroxisome-proliferator-activated receptor gamma resistance.
Chatterjee VK
Biochem Soc Trans; 2001 May; 29(Pt 2):227-31. PubMed ID: 11356159
[TBL] [Abstract][Full Text] [Related]
2. Resistance to thyroid hormone.
Chatterjee VK
Horm Res; 1997; 48 Suppl 4():43-6. PubMed ID: 9350446
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Agostini M; Gurnell M; Savage DB; Wood EM; Smith AG; Rajanayagam O; Garnes KT; Levinson SH; Xu HE; Schwabe JW; Willson TM; O'Rahilly S; Chatterjee VK
Endocrinology; 2004 Apr; 145(4):1527-38. PubMed ID: 14657011
[TBL] [Abstract][Full Text] [Related]
4. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.
Barroso I; Gurnell M; Crowley VE; Agostini M; Schwabe JW; Soos MA; Maslen GL; Williams TD; Lewis H; Schafer AJ; Chatterjee VK; O'Rahilly S
Nature; 1999 Dec 23-30; 402(6764):880-3. PubMed ID: 10622252
[TBL] [Abstract][Full Text] [Related]
5. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
Gurnell M; Wentworth JM; Agostini M; Adams M; Collingwood TN; Provenzano C; Browne PO; Rajanayagam O; Burris TP; Schwabe JW; Lazar MA; Chatterjee VK
J Biol Chem; 2000 Feb; 275(8):5754-9. PubMed ID: 10681562
[TBL] [Abstract][Full Text] [Related]
6. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.
Collingwood TN; Wagner R; Matthews CH; Clifton-Bligh RJ; Gurnell M; Rajanayagam O; Agostini M; Fletterick RJ; Beck-Peccoz P; Reinhardt W; Binder G; Ranke MB; Hermus A; Hesch RD; Lazarus J; Newrick P; Parfitt V; Raggatt P; de Zegher F; Chatterjee VK
EMBO J; 1998 Aug; 17(16):4760-70. PubMed ID: 9707435
[TBL] [Abstract][Full Text] [Related]
7. Isoform variable action among thyroid hormone receptor mutants provides insight into pituitary resistance to thyroid hormone.
Safer JD; Langlois MF; Cohen R; Monden T; John-Hope D; Madura J; Hollenberg AN; Wondisford FE
Mol Endocrinol; 1997 Jan; 11(1):16-26. PubMed ID: 8994184
[TBL] [Abstract][Full Text] [Related]
8. Five new families with resistance to thyroid hormone not caused by mutations in the thyroid hormone receptor beta gene.
Pohlenz J; Weiss RE; Macchia PE; Pannain S; Lau IT; Ho H; Refetoff S
J Clin Endocrinol Metab; 1999 Nov; 84(11):3919-28. PubMed ID: 10566629
[TBL] [Abstract][Full Text] [Related]
9. Thyroid hormone receptor beta mutants: Dominant negative regulators of peroxisome proliferator-activated receptor gamma action.
Araki O; Ying H; Furuya F; Zhu X; Cheng SY
Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16251-6. PubMed ID: 16260719
[TBL] [Abstract][Full Text] [Related]
10. A novel thyroid hormone receptor-beta mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone.
Wu SY; Cohen RN; Simsek E; Senses DA; Yar NE; Grasberger H; Noel J; Refetoff S; Weiss RE
J Clin Endocrinol Metab; 2006 May; 91(5):1887-95. PubMed ID: 16464943
[TBL] [Abstract][Full Text] [Related]
11. Introducing a point mutation identified in a patient with pituitary resistance to thyroid hormone (Arg 338 to Trp) into other mutant thyroid hormone receptors weakens their dominant negative activities.
Ando S; Nakamura H; Sasaki S; Nishiyama K; Kitahara A; Nagasawa S; Mikami T; Natsume H; Genma R; Yoshimi T
J Endocrinol; 1996 Nov; 151(2):293-300. PubMed ID: 8958790
[TBL] [Abstract][Full Text] [Related]
12. Hormone-nuclear receptor interactions in health and disease. Thyroid hormone resistance.
Chatterjee VK; Beck-Peccoz P
Baillieres Clin Endocrinol Metab; 1994 Apr; 8(2):267-83. PubMed ID: 8092973
[TBL] [Abstract][Full Text] [Related]
13. Syndrome of resistance to thyroid hormone: insights into thyroid hormone action.
Kopp P; Kitajima K; Jameson JL
Proc Soc Exp Biol Med; 1996 Jan; 211(1):49-61. PubMed ID: 8594618
[TBL] [Abstract][Full Text] [Related]
14. A novel mutation (E333D) in the thyroid hormone beta receptor causing resistance to thyroid hormone syndrome.
Maraninchi M; Bourcigaux N; Dace A; El-Yazidi C; Malezet-Desmoulins C; Krempf M; Torresani J; Margotat A
Exp Clin Endocrinol Diabetes; 2006 Nov; 114(10):569-76. PubMed ID: 17177139
[TBL] [Abstract][Full Text] [Related]
15. A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators.
Collingwood TN; Rajanayagam O; Adams M; Wagner R; Cavaillès V; Kalkhoven E; Matthews C; Nystrom E; Stenlof K; Lindstedt G; Tisell L; Fletterick RJ; Parker MG; Chatterjee VK
Proc Natl Acad Sci U S A; 1997 Jan; 94(1):248-53. PubMed ID: 8990194
[TBL] [Abstract][Full Text] [Related]
16. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity.
Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S
J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558
[TBL] [Abstract][Full Text] [Related]
17. Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1).
Fozzatti L; Lu C; Kim DW; Park JW; Astapova I; Gavrilova O; Willingham MC; Hollenberg AN; Cheng SY
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17462-7. PubMed ID: 21987803
[TBL] [Abstract][Full Text] [Related]
18. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors.
Yoh SM; Chatterjee VK; Privalsky ML
Mol Endocrinol; 1997 Apr; 11(4):470-80. PubMed ID: 9092799
[TBL] [Abstract][Full Text] [Related]
19. Modulation of thyroid hormone action by mutant thyroid hormone receptors, c-erbA alpha 2 and peroxisome proliferator-activated receptor: evidence for different mechanisms of inhibition.
Meier-Heusler SC; Zhu X; Juge-Aubry C; Pernin A; Burger AG; Cheng SY; Meier CA
Mol Cell Endocrinol; 1995 Jan; 107(1):55-66. PubMed ID: 7796935
[TBL] [Abstract][Full Text] [Related]
20. Search for abnormalities of nuclear corepressors, coactivators, and a coregulator in families with resistance to thyroid hormone without mutations in thyroid hormone receptor beta or alpha genes.
Reutrakul S; Sadow PM; Pannain S; Pohlenz J; Carvalho GA; Macchia PE; Weiss RE; Refetoff S
J Clin Endocrinol Metab; 2000 Oct; 85(10):3609-17. PubMed ID: 11061510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
